Granted Patent
B2
US 12,383,572 · App. 18/087,345 · Granted Aug 12, 2025
Administration of an anti-activin-a compound to a subject
Inventors:
Huiquan Han (Thousand Oaks, CA); Christopher Michael Haqq (Newbury Park, CA); Isaac Ciechanover (Burlingame, CA); Xiaolan Zhou (Newbury Park, CA); John Zhao-Nian Lu (Alhambra, CA)
A61K31/704A61K31/7068A61K38/177A61K38/1796A61K39/3955A61K39/39558A61K45/06C07K16/22A61K2039/505A61K2039/545C07K2317/76
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention relates to methods of treating ovarian cancer in a subject by administering to the subject by evaluating the subject's expression levels of specific biomarkers or angiogenic an anti-activin-A compound, such as an anti-activin-A antibody or an activin-A-binding receptor. In some embodiments, at least two compounds are administered to the subject, where the first compound is an anti-activin A compound, and the second compound is a chemotherapeutic compound, for example capecitabine. The invention further relates to methods of identifying subjects for treatment factors.
Claims (5)
1. A method for treating serous ovarian cancer in a subject in need thereof comprising administering a therapeutically effective amount of an anti-activin-A antibody to the subject wherein the anti-activin-A antibody comprises:
(a) a light chain variable domain sequence comprising a sequence of amino acids of antibody A1 (SEQ ID NO: 267);
(b) a heavy chain variable domain sequence a sequence of amino acids of a heavy chain antibody A1 (SEQ ID NO: 268).
2. The method of claim 1 wherein the patient is also treated with capecitabine.
3. The method of claim 1 wherein the patient is also tread with a doxorubicin liquid complex.
Assignments (3)
MERGER
Recorded Jul 9, 2025
From: SANTA MARIA BIOTHERAPEUTICS, INC.
To: ATARA BIOTHERAPEUTICS, INC.
Reel/Frame 071651/0155 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 7, 2025
From: HAN, HUIQUAN; ZHOU, XIAOLAN; LU, JOHN ZHAO-NIAN
To: AMGEN INC.
Reel/Frame 071620/0333 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 7, 2025
From: HAQQ, CHRISTOPHER MICHAEL; CIECHANOVER, ISAAC
To: SANTA MARIA BIOTHERAPEUTICS, INC.
Reel/Frame 071620/0581 →
Continuity (5)
Division
14764288
Provisional Application
61815220
· Apr 23, 2013
Provisional Application
61759961
· Feb 1, 2013
References Cited (400)
US 3773919A
· Boswell et al.
· 1973
[cited by applicant]
US 4411993A
· Gillis
· 1983
[cited by applicant]
US 4543439A
· Frackelton et al.
· 1985
[cited by applicant]
US RE32011E
· Zimmerman et al.
· 1985
[cited by applicant]
US 4816567A
· Cabilly et al.
· 1989
[cited by applicant]
US 4902614A
· Wakabayashi et al.
· 1990
[cited by applicant]
US 4973577A
· Vale et al.
· 1990
[cited by applicant]
US 5011912A
· Hopp et al.
· 1991
[cited by applicant]
US 5545616A
· Woodruff
· 1996
[cited by applicant]
US 5567584A
· Sledziewski et al.
· 1996
[cited by applicant]
US 5595898A
· Robinson et al.
· 1997
[cited by applicant]
US 5627052A
· Schrader
· 1997
[cited by applicant]
US 5693493A
· Robinson et al.
· 1997
[cited by applicant]
US 5750375A
· Sledziewski et al.
· 1998
[cited by applicant]
US 5827733A
· Lee et al.
· 1998
[cited by applicant]
US 5859205A
· Adair et al.
· 1999
[cited by applicant]
US 5863738A
· Dijke et al.
· 1999
[cited by applicant]
US 5885794A
· Mathews et al.
· 1999
[cited by applicant]
US 5994618A
· Lee et al.
· 1999
[cited by applicant]
US 6096506A
· Lee et al.
· 2000
[cited by applicant]
US 6162896A
· Mathews et al.
· 2000
[cited by applicant]
US 6300129B1
· Lonberg et al.
· 2001
[cited by applicant]
US 6465239B1
· Lee et al.
· 2002
[cited by applicant]
US 6468535B1
· Lee et al.
· 2002
[cited by applicant]
US 6472179B2
· Stahl et al.
· 2002
[cited by applicant]
US 6500664B1
· Lee et al.
· 2002
[cited by applicant]
US 6599876B2
· Kojima
· 2003
[cited by applicant]
US 6607884B1
· Lee et al.
· 2003
[cited by applicant]
US 6656475B1
· Lee et al.
· 2003
[cited by applicant]
US 6812339B1
· Venter et al.
· 2004
[cited by applicant]
US 6858208B2
· Lee et al.
· 2005
[cited by applicant]
US 6891082B2
· Lee et al.
· 2005
[cited by applicant]
US 7166707B2
· Feige
· 2007
[cited by applicant]
US 7189827B2
· Feige
· 2007
[cited by applicant]
US 7399848B2
· Lee et al.
· 2008
[cited by applicant]
US 7442778B2
· Gegg et al.
· 2008
[cited by applicant]
US 7507412B2
· Burger et al.
· 2009
[cited by applicant]
US 7511012B2
· Han et al.
· 2009
[cited by applicant]
US 7534432B2
· Lee et al.
· 2009
[cited by applicant]
US 7566772B2
· Green et al.
· 2009
[cited by applicant]
US 7585500B2
· Foltz et al.
· 2009
[cited by applicant]
US 7645861B2
· Gegg et al.
· 2010
[cited by applicant]
US 7655764B2
· Gegg et al.
· 2010
[cited by applicant]
US 7655765B2
· Gegg et al.
· 2010
[cited by applicant]
US 7662931B2
· Gegg et al.
· 2010
[cited by applicant]
US 7709605B2
· Knopf et al.
· 2010
[cited by applicant]
US 7736653B2
· Kim et al.
· 2010
[cited by applicant]
US 7737260B2
· Kim et al.
· 2010
[cited by applicant]
US 7750127B2
· Gegg et al.
· 2010
[cited by applicant]
US 7750128B2
· Gegg et al.
· 2010
[cited by applicant]
US 7803923B2
· Han et al.
· 2010
[cited by applicant]
US 7842663B2
· Knopf et al.
· 2010
[cited by applicant]
US 7928075B2
· Han et al.
· 2011
[cited by applicant]
US 7947646B2
· Sun et al.
· 2011
[cited by applicant]
US 7964193B2
· Green et al.
· 2011
[cited by applicant]
US 7994302B2
· Foltz et al.
· 2011
[cited by applicant]
US 8058229B2
· Seehra et al.
· 2011
[cited by applicant]
US 8067562B2
· Han et al.
· 2011
[cited by applicant]
US 8071538B2
· Han et al.
· 2011
[cited by applicant]
US 8110665B2
· Kim et al.
· 2012
[cited by applicant]
US 8124094B2
· Kim et al.
· 2012
[cited by applicant]
US 8128933B2
· Knopf et al.
· 2012
[cited by applicant]
US 8138142B2
· Seehra et al.
· 2012
[cited by applicant]
US 8178488B2
· Knopf et al.
· 2012
[cited by applicant]
US 8216997B2
· Seehra et al.
· 2012
[cited by applicant]
US 8252900B2
· Knopf et al.
· 2012
[cited by applicant]
US 8309082B2
· Han et al.
· 2012
[cited by applicant]
US 8343933B2
· Knopf et al.
· 2013
[cited by applicant]
US 8361957B2
· Seehra et al.
· 2013
[cited by applicant]
US 8410043B2
· Sun et al.
· 2013
[cited by applicant]
US 8501678B2
· Sun et al.
· 2013
[cited by applicant]
US 8614292B2
· Han et al.
· 2013
[cited by applicant]
US 8716459B2
· Sun et al.
· 2014
[cited by applicant]
US 8753627B2
· Han et al.
· 2014
[cited by applicant]
US 8999917B2
· Sun et al.
· 2015
[cited by applicant]
US 9273114B2
· Sun et al.
· 2016
[cited by applicant]
US 9284364B2
· Han et al.
· 2016
[cited by applicant]
US 20040209805A1
· Phillips et al.
· 2004
[cited by applicant]
US 20040223966A1
· Wolfman et al.
· 2004
[cited by applicant]
US 20050186593A1
· Mathews et al.
· 2005
[cited by applicant]
US 20060034831A1
· Tobin
· 2006
[cited by applicant]
US 20080089897A1
· Wolfman
· 2008
[cited by applicant]
US 20080248047A1
· Das et al.
· 2008
[cited by applicant]
US 20090087433A1
· Wolfman et al.
· 2009
[cited by applicant]
US 20100008918A1
· Sherman et al.
· 2010
[cited by applicant]
US 20110070233A1
· Seehra et al.
· 2011
[cited by applicant]
US 20120121576A1
· Seehra et al.
· 2012
[cited by applicant]
US 20120295814A1
· Cramer et al.
· 2012
[cited by applicant]
US 20140220033A1
· Han et al.
· 2014
[cited by applicant]
US 20150086556A1
· Han et al.
· 2015
[cited by applicant]
US 20150231206A1
· Sun et al.
· 2015
[cited by applicant]
US 20150359850A1
· Han et al.
· 2015
[cited by applicant]
US 20160152683A1
· Han et al.
· 2016
[cited by applicant]
CA 1219215A
· 1987
[cited by applicant]
CN 1946382A
· 2007
[cited by applicant]
CN 101679980A
· 2010
[cited by applicant]
EP 0036676A1
· 1981
[cited by applicant]
EP 0058481A1
· 1982
[cited by applicant]
EP 0088046A2
· 1983
[cited by applicant]
EP 0133988A2
· 1985
[cited by applicant]
EP 0143949A1
· 1985
[cited by applicant]
EP 2064239A2
· 2009
[cited by applicant]
EP 2370463A2
· 2011
[cited by applicant]
EP 2559705A2
· 2013
[cited by applicant]
JP 1171495A
· 1989
[cited by applicant]
JP 2006516886A
· 2006
[cited by applicant]
JP 2009513162A
· 2009
[cited by applicant]
JP 2010518009A
· 2010
[cited by applicant]
JP 2010519931A
· 2010
[cited by applicant]
JP 2010539236A
· 2010
[cited by applicant]
JP 2013027391A
· 2013
[cited by applicant]
JP 5349966A
· 2013
[cited by applicant]
JP 2014195469A
· 2014
[cited by applicant]
KR 101428344
· 2014
[cited by applicant]
WO 1992002551A1
· 1992
[cited by applicant]
WO 1993015722A1
· 1993
[cited by applicant]
WO 1994009817A1
· 1994
[cited by applicant]
WO 1994010332A1
· 1994
[cited by applicant]
WO 1994020069A1
· 1994
[cited by applicant]
WO 1999038890A1
· 1999
[cited by applicant]
WO 2000029581A1
· 2000
[cited by applicant]
WO 2000043781A2
· 2000
[cited by applicant]
WO 2000043781A3
· 2000
[cited by applicant]
WO 2004039948A2
· 2004
[cited by applicant]
WO 2004039948A3
· 2004
[cited by applicant]
WO 2005051299A2
· 2005
[cited by applicant]
WO 2005105057A1
· 2005
[cited by applicant]
WO 2005116052A2
· 2005
[cited by applicant]
WO 2006012627A2
· 2006
[cited by applicant]
WO 2006020884A2
· 2006
[cited by applicant]
WO 2006020884A3
· 2006
[cited by applicant]
WO 2006116269A2
· 2006
[cited by applicant]
WO 2007053775A1
· 2007
[cited by applicant]
WO 2008031061A2
· 2008
[cited by applicant]
WO 2008097541A2
· 2008
[cited by applicant]
WO 2008109167A2
· 2008
[cited by applicant]
WO 2008113185A1
· 2008
[cited by applicant]
WO 2010019261A1
· 2010
[cited by applicant]
WO 2010062383A2
· 2010
[cited by applicant]
WO 2013106175A1
· 2013
[cited by applicant]
WO 2014121221A1
· 2014
[cited by applicant]
WO 2015108972A1
· 2015
[cited by applicant]
WO 2015192127A2
· 2015
[cited by applicant]
Cooke and Brenton, Lancet Oncol 12: 1169-1174, ( 2011).
[cited by examiner]
Chamow and Ashkenazi, Tibtech 14: 52-60, (1996).
[cited by examiner]
Rudikoff et al., Proc. Natl. Acad. Sci. 79: 1979-1983, (1982).
[cited by examiner]
Abaza, MS., et al. “Effects of amino acid substitutions outside an antigenic site on protein binding to monoclonal antibodies of predetermined specificity obtained by peptide immunization: demonstration with region 94-1…
[cited by applicant]
Akerstrom, B et al., “Protein G: A Powerful Tool for Binding and Detection of Monoclonal and Polyclonal Antibodies,” Journal of Immunoloav, 135(4):2589-2592, 1985.
[cited by applicant]
Alibhai, SMH, et al., “Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review,” Crit Rev Oncol/Hematol. 2006, vol. 60, pp. 201-215.
[cited by applicant]
Anker, S., et al., “Cardiac Cachexia: A Syndrome With Impaired Survival and Immune and Neuroendocrine Activation,” Chest, 1999, vol. 115, pp. 836-847.
[cited by applicant]
Attisano, L., et al., “Activation of Signalling by the Activin Receptor Complex,” Molecular and Cellular Biology, Mar. 1996, p. 1066-1073, vol. 16. No. 3.
[cited by applicant]
Attisano, L., et al., “Novel Activin Receptors: Distinct Genes and Alternative mRNA Splicing Generate a Repertoire of Serine/Threonine Kinase Receptors,” Cell, Jan. 1992, vol. 68, pp. 97-108.
[cited by applicant]
Augustin, H.G., et al., “Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system,” Nature Reviews Molecular Cell Biology, 2009, vol. 10, pp. 165-177.
[cited by applicant]
Babcock, J., et al., “A Novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities,” Proc. Natl. Acad. Sci., USA, Jul. 1996, vol. 93, pp. 7843-784…
[cited by applicant]
Barany, et al., “Solid-phase peptide syntheses: a silver anniversary report,” Int. J. Peptide Protein Res., 30:705-739, 1987.
[cited by applicant]
Barany, et al., “Solid-phase peptide synthesis,” Ch. 1, The Peptides: Analysis, Synthesis, Biology, vol. 2, Gross and Meienhofer, eds., (Academic Press, New York, 1980), pp. 1-284.
[cited by applicant]
Beiboer, et al.,“Guided selection of a pan carcinoma specific antibody reveals similar binding characteristics yet structural divergence between the original murine antibody and its human equivalent,” J. Mol., Biol. (20…
[cited by applicant]
Berrondo, M., “Predicting the structure and function of protein mutants,” A Dissertation submitted to Johns Hopkins University in conformity with the requirements for the degree of Doctor of Philosophy Baltimore, Maryla…
[cited by applicant]
Birtalan, A., et al., “The intrinsic contributions of tyrosine, serine, glycine and arginine to the affinity and specificity of antibodies,” J. Mol. Biology, Apr. 2008, pp. 1518-1528, vol. 377.
[cited by applicant]
Bogdanovich, S., et al., “Myostatin blockade improves function but not histopathology in a murine model of limb-girdle muscular dystrophy 2C,” Muscle Nerve, Mar. 2008, pp. 308-316, vol. 37, No. 3.
[cited by applicant]
Bowie, J.U., et al., “Deciphering the message in protein sequences: tolerance to amino acid substitutions” Science, Mar. 16, 1990, pp. 1306-1310, vol. 247, No. 4948.
[cited by applicant]
Brown, et al., “Tolerance of single, but not multiple, amino acid replacements in antibody VH CDR 2: a means of minimizing B cell wastage from somatic hypermutation?” J. Immuno. May 1996, 3285-91.
[cited by applicant]
Campbell, K., et al., “Totipotency of Multipotentiality of Cultured Cells: Applications and Progress,” Theriogenology, Jan. 1, 1997, vol. 47, Issue 1, pp. 63-72.
[cited by applicant]
Casset, et al. “A peptide mimetic of an anti-CD4 monoclonal antibody by rational design,” Biochem Biophys Res Commun. Jul. 18, 2003, 307(1):198-205.
[cited by applicant]
Chamow and Ashkenazi, “Immunoadhesins: principles and applications,”
[cited by applicant]
Chang, K.P., et al., “Overexpression of activin A in oral squamous cell carcinoma: association with poor prognosis and tumor progression,” Ann Surg Oncol. 2010, vol. 17, pp. 1945-1956.
[cited by applicant]
Chaubert, et al., “Simultaneous Double Immunoenzymatic Labeling: A New Procedure for the Histopathologic Routine, ” Modern Pathology, 10(6):585-591, 1997.
[cited by applicant]
Chien, et al., “Significant structural and functional change of an antigen-binding site by a distant amino acid substitution: proposal of a structural mechanism,” Proc Natl Acad Sci U S A. Jul. 1989, 86(14):5532-6.
[cited by applicant]
Choi, J.-H., et al., “Gonadotropins and ovarian cancer,” Endocrine Reviews, 2007, vol. 28, pp. 440-461.
[cited by applicant]
Choi, K.-C., et al., “Differential expression of activin/inhibin subunit and activin receptor mRNAs in normal neoplastic ovarian surface epithelium (OSE),” Molecular and Cellular Endocrinology, 2001, vol. 174, pp. 99-11…
[cited by applicant]
Cipriano, S., et al., “Follistatin Is a Modulator of Gonadal Tumor Progression and the Activin-Induced Wasting Syndrome in Inhibin-Deficient Mice,” Endocrinology, 2000, vol. 141, No. 7, pp. 2319-2327.
[cited by applicant]
Clackson, T., et al., “Making antibody fragments using phage display libraries,” Nature 352:624-628, 1991.
[cited by applicant]
Cobellis, L., et al., “High Concentrations of Activin A in the Peritoneal Fluid of Women With Epithelial Ovarian Cancer,” J. Soc. Gynecol. Investig. 2004, vol. 11, pp. 203-206.
[cited by applicant]
Coerver, K. A. et al., “Activin Signaling through Activin Receptor Type II Causes the Cachexia-Like Symtoms in Inhibin-Deficient Mice,” Molecular Endocrinology 10:534-543, 1996.
[cited by applicant]
Colman, PM., “Effects of amino acid sequence changes on antibody-antigen interactions,” Res Immunol. 145(1):33-36, 1994.
[cited by applicant]
Communication Pursuant to Article 94(3) EPC for European Patent Application No. 06827481.0, Jul. 20, 2010, 2 pages.
[cited by applicant]
Communication Pursuant to Article 94(3) EPC for European Patent Application No. 06827481.0, May 30, 2011, 3 pages.
[cited by applicant]
Communication Pursuant to Article 94(3) EPC for European Patent Application No. 06827481.0, Sep. 9, 2008, 2 pages.
[cited by applicant]
Communication Pursuant to Article 94(3) EPC for European Patent Application No. 07842088.2, Feb. 18, 2013, 4 Pages.
[cited by applicant]
Communication pursuant to Article 94(3) EPC for European Patent Application No. 07842088.2, Feb. 4, 2010, 3 Pages.
[cited by applicant]
Communication pursuant to Article 94(3) EPC for European Patent Application No. 07842088.2, Jan. 24, 2012, 6 Pages.
[cited by applicant]
Communication pursuant to Article 94(3) EPC for European Patent Application No. 07842088.2, Jul. 31, 2012, 4 Pages.
[cited by applicant]
Communication Pursuant to Article 94(3) EPC for European Patent Application No. 08742032.9, Apr. 18, 2013, 4 pages.
[cited by applicant]
Communication pursuant to Article 94(3) EPC for European Patent Application No. 08742032.9, Aug. 21, 2015, 3 Pages.
[cited by applicant]
Communication pursuant to Article 94(3) EPC for European Patent Application No. 09761055.4, Apr. 28, 2014, 3 Pages.
[cited by applicant]
Communication pursuant to Article 94(3) EPC for European Patent Application No. 09761055.4, Sep. 13, 2012, 2 pages.
[cited by applicant]
Communication pursuant to Article 94(3) EPC for European Patent Application No. 09761055.4, Sep. 3, 2013, 3 Pages.
[cited by applicant]
Communication pursuant to Article 94(3) EPC for European Patent Application No. 09761055.4, Sep. 9, 2014, 4 Pages.
[cited by applicant]
Communication pursuant to Article 94(3) EPC for European Patent Application No. 12154124.7, Feb. 17, 2014, 5 Pages.
[cited by applicant]
Communication pursuant to Article 94(3) EPC for European Patent Application No. 12809999.1, Dec. 22, 2016, 6 Pages.
[cited by applicant]
Communication Pursuant to Article 94(3) EPC for European Patent Application No. 12809999.1, Jan. 19, 2016, 4 Pages.
[cited by applicant]
Cooke and Brenton, “Evolution of platinum resistance in high-grade serous ovarian cancer,”
[cited by applicant]
Database EMBL Accession No. AY421275, “
[cited by applicant]
Database Geneseq Accession No. AAW86245, “Mouse ActRIIB4 receptor protein, ” Feb. 16, 1999, 1 Page.
[cited by applicant]
Database Geneseq Accession No. ADO43580, “Amino acid sequence of ActRIIB,” Jul. 29, 2004, 2 Pages.
[cited by applicant]
Database WPI Week 198933 Derwent Publications Ltd., London, GB; AN 1989-237375 XP002471408 & JP 01 171495 A (Ajinomoto KK) Jul. 6, 1989 (Jul. 6, 1989).
[cited by applicant]
De Kretser DM, et al., “Activin A and follistatin: their role in the acute phase reaction and inflammation,” Journal of Endocrinology. 1999, vol. 161, pp. 195-198.
[cited by applicant]
Decision of Rejection for Japanese Patent Application No. 2012-171705, Aug. 26, 2015, 5 Pages.
[cited by applicant]
Decision of Rejection for Japanese Patent Application No. 2013-030740, Jan. 6, 2016, 7 Pages.
[cited by applicant]
Decision on Examination for Taiwan Patent Application No. 097107642, Aug. 29, 2012, 4 Pages.
[cited by applicant]
Dennler, et al., “Direct binding of Smad3 and Smad4 to critical TGF.beta.-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene,” The EMBO Journal, 17(11):3091-3100, 1998.
[cited by applicant]
Derynck, R., et al., “Smads: Transcriptional Activators of TGF-β Responses,” Cell, Dec. 11, 1998, vol. 95, pp. 737-740.
[cited by applicant]
Do, TV, “The role of activin A and Akt/GSK signaling in ovarian tumor biology,” Endocrinology. 2008, vol. 149, pp. 3809-3816.
[cited by applicant]
Doherty, TJ, “Aging and Sarcopenia,” J Appl Physiol, 2003, 95:1717-1727.
[cited by applicant]
Donaldson et al., “Activin and Inhibin Binding to the Soluble Extracellular Domain of Activin Receptor II, ” Endocrinology, 140(4):1760-1766, 1999.
[cited by applicant]
Draper, L., et al., “The Unterine Myometrium Is a Target for Increased Levels of Activin A During Pregnancy,” Endocrinology, 1997, vol. 137, No. 7, pp. 3042-3046.
[cited by applicant]
Durocher, et al., “High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells,” Nucleic Acids Research, 30(2e9) 2002, 9 Pages.
[cited by applicant]
Dvorak, H.F., et al., “Tumor microenvironment and progression,” Journal of Surgical Oncology, 2011, vol. 103, pp. 468-474.
[cited by applicant]
EBI, Swissprot Accession No. 095390, GDF11.sub.—Human, Growth/differentiation factor 11, 2 pages., [online] [retrieved on Sep. 9, 2010] Retrieved from the internet <URL:http://www.ebi.ac.uk/uniprot/unisave/?help-O&sessi…
[cited by applicant]
Ellis, L.M., et al., “VEGF-targeted therapy: mechanisms of antitumour activity,” Nature Reviews Cancer, 2008, vol. 8, pp. 579-591.
[cited by applicant]
Eppstein, et al., “Biological activity of liposome-encapsulated murine interferon .gamma. is mediated by a cell membrane receptor,” Proc. Natl. Acad. Sci. USA, 82:3688-3692, 1985.
[cited by applicant]
Ethier, J-F., et al., “Bovine Activin Receptor Type IIB Messenger Ribonucleic Acid Displays Alternative Splicing Involving a Sequence Homologous to Src-Homology 3 domain Binding Sites,” Endocrinology, Jun. 1997, vol. 13…
[cited by applicant]
European Examination Report for European U.S. Appl. No. 12/154,124. 7, Oct. 16, 2014, 4 pages.
[cited by applicant]
Examination Report No. 1 for Australian Patent Application No. 2009320364, Nov. 30, 2011, 2 pages.
[cited by applicant]
Examination Report for Australian Patent Application No. 2012364736, Oct. 19, 2016, 3 Pages.
[cited by applicant]
Examination Report for Australian Patent Application No. 2013216639, Apr. 30, 2015, 4 Pages.
[cited by applicant]
Examination Report No. 2 for Australian Patent Application No. 2014210609, May 23, 2016, 2 Pages.
[cited by applicant]
Examination Report for Australian Patent Application No. 2014210609, Sep. 23, 2015, 2 Pages.
[cited by applicant]
Examination Report No. 2 for Australian Patent Application No. 2016210719, Mar. 23, 2017, 2 Pages.
[cited by applicant]
Examination Report No. 1 for Australian Patent Application No. 2016219676, Feb. 23, 2017, 2 Pages.
[cited by applicant]
Examination Report for Gulf Cooperation Council Application No. GCC/P/2008/10291, Sep. 7, 2012, 6 pages.
[cited by applicant]
Examination Report for Malaysia Patent Application No. PI20093636, Dec. 31, 2013, 3 Pages.
[cited by applicant]
Examination Report from the Intellectual Property Office for Taiwan Patent Application No. 098140431, Jun. 18, 2012, 11 pages.
[cited by applicant]
Examiner's First Report for Canadian Patent Application No. 2,627,200, Jun. 7, 2010, 3 pages.
[cited by applicant]
Examiner's Second Report for Canadian Patent Application No. 2,627,200, Nov. 2, 2011, 2 pages.
[cited by applicant]
Examiner's Third Report for Canadian Patent Application No. 2,627,200, May 28, 2012, 1 page.
[cited by applicant]
Extended European Search Report for European Patent Application No. 16194631.4, Jan. 26, 2017, 7 Pages.
[cited by applicant]
Extended European Search Report for European Patent Application No. 16179980.4, Sep. 7, 2016, 7 Pages.
[cited by applicant]
Extended European Search Report for European Patent Application No. 16178026.7, Jan. 23, 2017, 9 Pages.
[cited by applicant]
Extended European Search Report for European Patent Application No. 12154124.7, May 8, 2013, 12 Pages.
[cited by applicant]
Final Rejection Office Action for Japanese Patent Application No. 2009-552758, Aug. 1, 2013, 5 Pages.
[cited by applicant]
First Examination Report for India Application No. 6356/DELNP/2009, Jan. 20, 2015, 3 pages.
[cited by applicant]
First Examination Report for New Zealand Patent Application No. 604818, Jan. 8, 2013, 2 Pages.
[cited by applicant]
First Examination Report for New Zealand Patent Application No. 627111, Jul. 24, 2014, 1 page.
[cited by applicant]
First Examination Report for New Zealand Patent Application No. 626580, Mar. 18, 2015, 2 Pages.
[cited by applicant]
First Examination Report for New Zealand Patent Application No. 720036, May 31, 2016, 3 Pages.
[cited by applicant]
First Office Action for Chinese Patent Application No. 200980147945.3, Mar. 21, 2013, 13 Pages.
[cited by applicant]
First Office Action for Eurasian Patent Application No. 2009708/28, Sep. 15, 2011, 2 Pages.
[cited by applicant]
Fujii, Y., et al., “Regulation of prostate-specific antigen by activin A in prostate cancer LNCaP cells,” Am. J. Physiol. Endocrinol. Metab., 2004, vol. 286, pp. E927-E931.
[cited by applicant]
Funaba, et al., “Unique Recognition of Activin and Inhibin by Polyclonal Antibodies to Inhibin Subunits,” J. Biochem. 119:953-960, 1996.
[cited by applicant]
Gabizon A, et al., “Polyethylene glycol-coated (pegylated) liposomal doxorubicin: rationale for use in solid tumours,” Drugs. 1997, vol. 54 (suppl 4), pp. 15-21.
[cited by applicant]
Gaedeke, J., et al., “Glomerular activin A overexpression is linked to fibrosis in anti-Thy1 glomerulonephritis,” Nephrol. Dial. Transplant, 2005, vol. 20, pp. 319-328.
[cited by applicant]
Gamer, L., et al., “A Novel BMP Expressed in Developing Mouse Limb, Spinal Cord, and Tail Bud Is a Potent Mesoderm Inducer in Xenopus Embryos,” Developmental Biology, 1999, vol. 208, No. 1, pp. 222-232.
[cited by applicant]
Geisse, S., et al., “Eukaryotic Expression Systems: A Comparison,” Protein Expression and Purification, Nov. 1996, pp. 271-282, vol. 8, Is. 3, Academic Press, Inc.
[cited by applicant]
Gibbs, R., et al., “Evolutionary and Biomedical Insights from the Rhesus Macaque Genome,” Science, Apr. 13, 2007, pp. 222-234, vol. 316.
[cited by applicant]
Gluzman, et al., “SV40-Transformed Simian Cells Support the Replication of Early SV40 Mutants,” Cell, 23:175-182, 1981.
[cited by applicant]
Gonzalez-Cadavid, N., et al., “Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting,” PNAS USA, 1998, vol. 95, pp. 14938-14943.
[cited by applicant]
Gray, P., et al., “Identification of a Binding Site on the Type II Activin Receptor for Activin and Inhibin,” J. Biol. Chem., Feb. 4, 2000, vol. 275, No. 5, pp. 3206-3212.
[cited by applicant]
Groome, N., et al., “Preparation of monoclonal Antibodies to the Beta A Subunit of Ovarian Inhibin Using a Synthetic Peptide Immunogen,” Hybridoma, 1991, vol. 10, No. 2, pp. 309-316.
[cited by applicant]
Hamrick, M., et al., “Bone Mineral Content and Density in the Humerus of Adult Myostatin-Deficient Mice,” Calcif Tissue Int, 2002, vol. 71, No. 1, pp. 63-68.
[cited by applicant]
Harada, K., et al., “Serum Immunoreactive Activin A Levels in Normal Subjects and Patients with Various Diseases,” Journal of Clinical Endocrinology and Metabolism, 1996, vol. 81, pp. 2125-2130.
[cited by applicant]
Harrison, C.A., et al., “Antagonists of activin signaling: mechanisms and potential biological applications,” Trends in Endocrinology and Metabolism, Mar. 2005, vol. 16, No. 2, pp. 73-78.
[cited by applicant]
Harrison, et al., “An Activin Mutant with Disrupted ALK4 Binding Blocks Signaling via Type II Receptors,” Journal of Biological Chemistry, 279(27):28036-28044, 2004.
[cited by applicant]
Hilden, K., et al., “Expression of Type II Activin Receptor Genes During Differentiation of Human K562 Cells and cDNA Cloning of the Human Type IIB Activin Receptor,” Blood, Apr. 15, 1994, pp. 2163-2170, vol. 83, No. 8.
[cited by applicant]
Holzbaur, E.L., et al., Myostatin inhibition slows muscle atrophy in rodent models of amyotrophic lateral sclerosis, Neurobioloav of Disease, 2006, pp. 697-707, vol. 23.
[cited by applicant]
Hopp, T., et al., “A Short Polypeptide Marker Sequence Useful for Recombinant Protein Identification and Purification,” Bio Technology, 1998, vol. 6, pp. 1204-1210.
[cited by applicant]
Hubner G, et al., “Activin: a novel player in tissue repair processes,” Histology & Histopathology. 1999, vol. 14, pp. 295-304.
[cited by applicant]
Intellectual Property Office of the Philippines, Notice of Allowance, Philippine Patent Application No. 1/2009/501698, Feb. 5, 2015, 1 page.
[cited by applicant]
Invitation to Respond to Written Opinion, Singapore Patent Application No. 201103777-7, Aug. 1, 2012, 5 pages.
[cited by applicant]
Ito, et al., “Presence of activin signal transduction in normal ovarian cells and epithelial ovarian carcinoma, ” British Journal of Cancer, 82(8): 1415-1420, 2000.
[cited by applicant]
Jones KL, et al., “Activin A and follistatin in systemic inflammation,” Molecular & Cellular Endocrinology. 2004, vol. 225, pp. 119-125.
[cited by applicant]
Jones, R., “Activin A and Inhibin A Differentially Regulate Human Uterine Matrix Metalloproteinases: Potential Interactions during Decidualization and Trophoblast Invasion,” Endocrinology, 2006, vol. 147, No. 2, pp. 724…
[cited by applicant]
Kaufman, R., et al., “Transgenic Analysis of a 100-kb Human β-Globin Cluster-Containing DNA Fragment Propagated as a Bacterial Artificial Chromosome,” Blood, Nov. 1, 1999, vol. 94, No. 9, pp. 3178-3184.
[cited by applicant]
Kinglsey, D., et al., “The TGF-β superfamily: new members, new receptors, and new genetic tests of function in different organisms,” Genes Dev., 1994, vol. 8, pp. 133-146.
[cited by applicant]
Klimka, et al., “Human anti-CD30 recombinant antibodies by guided phage antibody selection using cell panning,” British Journal of Cancer (2000) 83:252-260.
[cited by applicant]
Konishi, I. “Gonadotropins and ovarian carcinogenesis: a new era of basic research and its clinical implications,” Int J Gynecol Cancer, 2006, vol. 16, pp. 16-22.
[cited by applicant]
Kostelny, et al., “Formation of a Bispecific Antibody by the Use of Leucine Zippers,” Journal of Immunology, 148(5):1547-1553, 1992.
[cited by applicant]
Kwak, K.S., et al., “Regulation of protein catabolismby muscle-specific and cytokine-inducible ubiquitin ligase E3alpha-11 during cancer cachexia,” Cancer Res, 2004, vol. 64, pp. 8193-8198.
[cited by applicant]
Lalani, R., et al., “Myostatin and insulin-like growth factor-I and -II expression in the muscle of rafts exposed to the microgravity environment of the NeuroLab space shuttle flight,” Journal of Endocrinology, 2000, vo…
[cited by applicant]
Lambert-Messerlian, G.M., et al., “Secretion of Activin A in Recurrent Epithelial Ovarian Carcinoma,” Gynecologic Oncology, 1999, vol. 74, pp. 93-97.
[cited by applicant]
Lang, C., et al., “Regulation of myostatin by glucocorticoids after thermal injury,” FASEB, 2001, vol. 1, No. 15, pp. 1807-1809.
[cited by applicant]
Langer, R., “Controlled release of macromolecules,” ChemTech, 12:98-105, 1982.
[cited by applicant]
Langer, R., et al., “Biocompatibility of polymeric delivery systems for macromolecules,” J. of Biomedical Materials Research, 15:267-277, 1981.
[cited by applicant]
Lederman, S., et al., “A single amino acid substitution in a common African allele of the CD4 molecule ablates binding of the monoclonal antibody,” OKT4. Mol Immunol. 28(11):1171-81, 1991.
[cited by applicant]
Lee SJ, et al., “Regulation of muscle growth by multiple ligands signaling through activin type II receptors,” Proc Nati Acad Sci USA. 2005, vol. 102, pp. 18117-18122.
[cited by applicant]
Lee SJ, et al., “Regulation of myostatin activity and muscle growth,” Proc Natl. Acad. Sci., USA. 2001, vol. 98, pp. 9306-9311.
[cited by applicant]
Li et al., “Activin A Binds to Perlecan through Its Pro-region That Has Heparin/Heparan Sulfate Binding Activity,” JBC, 285(47)36645-36655, 2010.
[cited by applicant]
Ling, N., et al., “Pituitary FSH is released by a heterodimer of the β-subunits from the two forms of inhibin,” Nature, 1986, vol. 321, pp. 779-782.
[cited by applicant]
Longfellow, C., et al., “Thermodynamic and Spectroscopic Study of Bulge Loops in Oligoribonucleoptides,” Biochemistry, 1990, vol. 29, pp. 278-285.
[cited by applicant]
Luisi S, et al., “Expression and secretion of activin A: possible physiological and clinical implications,” European Journal of Endocrinology. 2001, vol. 145, pp. 225-236.
[cited by applicant]
Maccallum, et al., “Antibody-antigen interactions: contact analysis and binding site topography,” J Mol Biol. Oct. 11, 1996, 262(5):732-45.
[cited by applicant]
MacDonald N, et al., “Understanding and managing cancer cachexia,” J Am Coll Surg. 2003, vol. 197, pp. 143-161.
[cited by applicant]
Macias-Silva, et al., “MADR2 Is a Substrate of the TGF.beta. Receptor and Its Phosphorylation Is Required for Nuclear Accumulation and Signaling, ” Cell, 87:1215-1224, 1996.
[cited by applicant]
Mason, A., et al., “Complementary DNA sequences of ovarian follicular fluid inhibin show precursor structure and homology with transforming growth factor-β,” Nature, Dec. 1985, pp. 659-663, vol. 318.
[cited by applicant]
Massague, J., “How Cells Read TGF-β Signals,” Nature Rev: Molecular Cell Biology, 2000, pp. 169-178, vol. 1.
[cited by applicant]
Mathews, L.S., “Activin Receptors and Cellular Signaling by the Receptor Serine Kinase Family,” Endocrine Review, 1994, vol. 15, pp. 310-325.
[cited by applicant]
Matzuk MM, et al., “Development of cancer cachexia-like syndrome and adrenal tumors in inhibin-deficient mice,” Proc Nati Acad Sci USA. 1994, vol. 91, pp. 8817-8321.
[cited by applicant]
Matzuk MM, et al., “α-inhibin is a tumour-suppressor gene with gonadal specificity in mice,” Nature. 1992, vol. 360, pp. 313-319.
[cited by applicant]
McMahan, et al., “A novel IL-1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types,” The EMBO Journal, 10(10):2821-2832, 1991.
[cited by applicant]
McPherron, A., et al., “Regulation of anterior/posterior patterning of the axial skeleton by growth/differentiation factor 11,” Natr Genet, 1999, vol. 22, No. 93, pp. 260-264.
[cited by applicant]
McPherron, A., et al., “Regulation of skeletal muscle mass in mice by a new TGF-β superfamily member,” Nature (London), May 1997, vol. 387, pp. 83-90.
[cited by applicant]
Mcpherron, et al., “Double muscling in cattle due to mutations in the myostatin gene,” Proc. Natl. Acad. Sci. USA, 94:12457-12461, 1997.
[cited by applicant]
Mcpherron, et al., “The Transforming Growth Factor B Superfamily,” in Growth Factors and Cytokines in Health and Disease, vol. 1B, D. LeRoith and C. Bondy, eds., (JAI Press Inc., Greenwich, Ct, USA), pp. 357-393, 1996.
[cited by applicant]
Mendez, et al., “Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice,” Nature Genetics 15:146-156, 1997.
[cited by applicant]
Menon, U., et al., “Serum inhibin, activin and follistatin in postmenopausal women with epithelial ovarian carcinoma,” British Journal of Obstetrics and Gynecology, 2000, vol. 107, pp. 1069-1074.
[cited by applicant]
Merrifield, B., “Solid Phase Synthesis,” Science, 232:341-347, 1986.
[cited by applicant]
Mikaelian, et al., “Modification of the Overlap Extension Method for Extensive Mutagenesis on the Same Template, ” Methods in Molecular Biology, 57:193-202, 1996.
[cited by applicant]
Morley JE, et al., “Cachexia: pathophysiology and clinical relevance,” Am J Clin Nutr. 2006, vol. 83, pp. 735-743.
[cited by applicant]
Muscaritoli M, et al., “Prevention and treatment of cancer cachexia: new insights into an old problem,” Eur J Cancer. 2006, vol. 42, pp. 31-41.
[cited by applicant]
NCBI, “Activin receptor type-2B precursor [
[cited by applicant]
NCBI, GenBank: AAN76043.1 “immunoglobulin gamma 2 heavy chain constant region, partial [
[cited by applicant]
NCBI, “Genbank Accession No. AAB86694, myostatin [
[cited by applicant]
NCBI, “Genbank Accession No. NM 002192,
[cited by applicant]
NCBI, “Genbank Accession No. NP 001097, activin receptor type-2B precursor [
[cited by applicant]
NCBI, “Myostatin [
[cited by applicant]
NCBI, “
[cited by applicant]
Ngo, J.T., et al., “Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox,” The Protein Folding Problem and Tertiary Structure Prediction, pp. 492-495, 1994.
[cited by applicant]
Notice of Final Rejection for Korean Patent Application No. 2009-7020320, Sep. 4, 2012, 2 Pages.
[cited by applicant]
Notice of Preliminary Rejection Office Action Summary for Korean Patent Application No. 2012-7008467, Apr. 18, 2013, 3 pages (English Translation).
[cited by applicant]
Notice of Reasons for Rejection for Japanese Patent Application No. 2009-527594, Nov. 21, 2012, 16 pages.
[cited by applicant]
Notice of Reasons for Rejection for Japanese Patent Application No. 2014-136375, Feb. 15, 2016, 6 Pages.
[cited by applicant]
Notice of Reasons for Rejection for Japanese Patent Application No. 2013-030740, Jun. 3, 2015, 8 Pages.
[cited by applicant]
Notice of Reasons for Rejection for Japanese Patent Application No. 2012-171705, Oct. 31, 2016, 13 Pages.
[cited by applicant]
Notification of Grounds for Rejection for Japanese Patent Application No. 2009-527594, Sep. 12, 2013, 6 Pages.
[cited by applicant]
Notification of Reasons for Rejection for Japanese Patent Application No. 2008-539077, Dec. 19, 2012, 5 Pages.
[cited by applicant]
Notification of Reasons for Rejection for Japanese Patent Application No. 2008-539077, Feb. 2, 2012, 3 pages.
[cited by applicant]
Notification of Reexamination Board Opinion for Chinese Patent Application No. 200880007116.0, Apr. 3, 2015, 11 Pages.
[cited by applicant]
O'connor, A.E., et al., “Serum activin A and follistatin concentrations during human pregnancy: a cross-sectional and longitudinal study,” Human Reproduction, 1999, vol. 14, No. 3, pp. 827-832.
[cited by applicant]
Office Action for Argentine Published Patent Application No. 074397 A1, Jan. 9, 2017, 7 Pages.
[cited by applicant]
Office Action for Argentine Published Patent Application No. 065611 A1, Mar. 10, 2017, 8 Pages (With English Summary).
[cited by applicant]
Office Action for Canadian Patent Application No. 2,661,878, Jan. 25, 2017, 6 Pages.
[cited by applicant]
Office Action for Canadian Patent Application No. 2,661,878, Jan. 10, 2014, 4 Pages.
[cited by applicant]
Office Action for Canadian Patent Application No. 2,661,878, Nov. 10, 2015, 6 Pages.
[cited by applicant]
Office Action for Canadian Patent Application No. 2,661,878, Oct. 28, 2014, 4 pages.
[cited by applicant]
Office Action for Canadian Patent Application No. 2,679,841, Apr. 26, 2016, 4 Pages.
[cited by applicant]
Office Action for Canadian Patent Application No. 2,679,841, Apr. 28, 2014, 2 Pages.
[cited by applicant]
Office Action for Canadian Patent Application No. 2,679,841, Apr. 8, 2013, 2 Pages.
[cited by applicant]
Office Action for Canadian Patent Application No. 2,743,850, Oct. 24, 2013, 2 Pages.
[cited by applicant]
Office Action for Canadian Patent Application No. 2,743,850, Nov. 6, 2014, 3 pages.
[cited by applicant]
Office Action for Canadian Patent Application No. 2,743,850, Oct. 19, 2015, 4 pages.
[cited by applicant]
Office Action for Canadian Patent Application No. 2,743,850, Sep. 5, 2012, 4 pages.
[cited by applicant]
Office Action for Canadian Patent Application No. 2,743,850, Sep. 9, 2016, 3 Pages.
[cited by applicant]
Office Action for Chilean Patent Application No. 2015-03139, Apr. 12, 2017, 8 Pages (With Concise Explanation of Relevance).
[cited by applicant]
Office Action for Chilean Patent Application No. 2015-02166, Feb. 13, 2017, 13 Pages.
[cited by applicant]
Office Action for Chilean Patent Application No. 2014-01648, Feb. 15, 2017, 19 Pages.
[cited by applicant]
Office Action for Chilean Patent Application No. 2014-01648, Feb. 9, 2016, 18 Pages.
[cited by applicant]
Office Action for Chilean Patent Application No. 1239-2011, Apr. 27, 2014, 75 Pages.
[cited by applicant]
Office Action for Chinese Patent Application No. 201410462932.8, Nov. 28, 2016, 6 pages, (With Concise Explanation of Relevance).
[cited by applicant]
Office Action for Chinese Patent Application No. 2012800701034, Sep. 18, 2015, 12 Pages. (With Concise Explanation of Relevance).
[cited by applicant]
Office Action for Chinese Patent Application No. 201280070103.4, Dec. 27, 2016, 11 Pages, (With Concise Explanation of Relevance).
[cited by applicant]
Office Action for Chinese Patent Application No. 200880007116.0, Feb. 22, 2013, 13 Pages.
[cited by applicant]
Office Action for Colombian Patent Application No. 14-143018, Apr. 6, 2016, 26 Pages.
[cited by applicant]
Office Action for Colombian Patent Application No. 11-079.058, Oct. 31, 2016, 12 Pages.
[cited by applicant]
Office Action for Colombian Patent Application No. 11-079.058, Apr. 12, 2016, 17 Pages.
[cited by applicant]
Office Action for Colombian Patent Application No. 11.079.058, May 14, 2014, 12 Pages.
[cited by applicant]
Office Action for Colombian Patent Application No. 11-79058-5, Nov. 27, 2012, 15 Pages.
[cited by applicant]
Office Action for Colombian Patent Application No. 11-79058-8, Jun. 17, 2013, 11 Pages.
[cited by applicant]
Office Action for Colombian Patent Application No. 1239-2011 Mailed on Jun. 18, 2013, 34 Pages.
[cited by applicant]
Office Action for Colombian Patent Application No. 14-143018, Dec. 16, 2016, 7 Pages.
[cited by applicant]
Office Action for Colombian Patent Application No. NC2016/0005077, May 2, 2017, 3 Pages (With English Summary).
[cited by applicant]
Office Action for Costa Rica Application No. 11054, Jan. 26, 2015, 15 pages.
[cited by applicant]
Office Action for Costa Rica Patent Application No. 11054, Sep. 17, 2015, 16 Pages. (With Concise Explanation of Relevance).
[cited by applicant]
Office Action for Costa Rica Patent Application No. 11054, Sep. 24, 2014, 9 Pages.
[cited by applicant]
Office Action for Egypt Patent Application No. PCT13142009, May 1, 2013, 11 Pages.
[cited by applicant]
Office Action for Eurasian Patent Application No. 201491231, Apr. 20, 2016, 4 Pages.
[cited by applicant]
Office Action for Eurasian Patent Application No. 201490822, Apr. 12, 2017, 2 Pages.
[cited by applicant]
Office Action for Eurasian Patent Application No. 201490822, May 5, 2016, 2 Pages (With Concise Explanation of Relevance).
[cited by applicant]
Office Action for Eurasian Patent Application No. 201491231, Nov. 25, 2016, 5 Pages.
[cited by applicant]
Office Action for Eurasian Patent Application No. 201100832, Nov. 28, 2014, 3 pages.
[cited by applicant]
Office Action for Eurasian Patent Application No. 201100832, Aug. 26, 2015, 2 Pages.
[cited by applicant]
Office Action for Eurasian Patent Application No. 201100832/28 Mailed on Feb. 27, 2014, 3 Pages.
[cited by applicant]
Office Action for Israeli Patent Application No. 200605, Aug. 7, 2014, 4 Pages.
[cited by applicant]
Office Action for Israeli Patent Application No. 212773, Jun. 28, 2015, 3 pages. (With Concise Explanation of Relevance).
[cited by applicant]
Office Action for Israeli Patent Application No. 240139, Feb. 28, 2016, 3 Pages. (With Concise Explanation of Relevance).
[cited by applicant]
Office Action for Israeli Patent Application No. 248128, Oct. 5, 2016, 3 Pages, (With Concise Explanation of Relevance).
[cited by applicant]
Office Action for Japanese Patent Application No. 2009-552758, Feb. 20, 2013, 2 Pages.
[cited by applicant]
Office Action for Japanese Patent Application No. 2011-538599 Mailed Apr. 17, 2014, 6 Pages.
[cited by applicant]
Office Action for Japanese Patent Application No. 2012-171705 mailed Apr. 2, 2014, 9 Pages.
[cited by applicant]
Office Action for Japanese Patent Application No. 2012-171705, Feb. 4, 2015, 8 pages.
[cited by applicant]
Office Action for Japanese Patent Application No. 2013-030740, Jul. 23, 2014, 12 Pages.
[cited by applicant]
Office Action for Japanese Patent Application No. 2014-177598, Oct. 14, 2015, 6 Pages.
[cited by applicant]
Office Action for Japanese Patent Application No. 2014-548827, Sep. 28, 2016, 7 Pages.
[cited by applicant]
Office Action for Japanese Patent Application No. 2016-092915, Mar. 29, 2017, 10 Pages.
[cited by applicant]
Office Action for Korean Patent Application No. 10-2012-7008467, Sep. 7, 2016, 6 Pages, (With Concise Explanation of Relevance).
[cited by applicant]
Office Action for Korean Patent Application No. 10-2011-7014720, Dec. 18, 2015, 7 Pages. (With Concise Explanation of Relevance).
[cited by applicant]